Bioclavid 500 mg + 125 mg filmovertrukne tabletter Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

bioclavid 500 mg + 125 mg filmovertrukne tabletter

sandoz gmbh - amoxicillintrihydrat, kaliumclavulanat - filmovertrukne tabletter - 500 mg + 125 mg

Myastad 360 mg enterotabletter Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

myastad 360 mg enterotabletter

stada arzneimittel ag - mycophenolatnatrium - enterotabletter - 360 mg

Lupkynis Europäische Union - Dänisch - EMA (European Medicines Agency)

lupkynis

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosuppressiva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Gaviscon tyggetabletter Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

gaviscon tyggetabletter

nordic drugs ab - alginsyre, aluminiumhydroxid, natriumhydrogencarbonat - tyggetabletter

Betaklav 500 mg+125 mg filmovertrukne tabletter Dänemark - Dänisch - Lægemiddelstyrelsen (Danish Medicines Agency)

betaklav 500 mg+125 mg filmovertrukne tabletter

krka sverige ab - amoxicillintrihydrat, clavulansyre - filmovertrukne tabletter - 500 mg+125 mg

Renagel Europäische Union - Dänisch - EMA (European Medicines Agency)

renagel

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle andre terapeutiske produkter - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Tasermity Europäische Union - Dänisch - EMA (European Medicines Agency)

tasermity

genzyme europe bv - sevelamer hydrochlorid - hyperphosphatemia; renal dialysis - alle andre terapeutiske produkter - tasermitet er indiceret til bekæmpelse af hyperphosphatæmi hos voksne patienter, der modtager hæmodialyse eller peritonealdialyse. sevelamer hydrochlorid bør anvendes inden for rammerne af en flere terapeutiske tilgang, som kunne omfatte kalktilskud, 1,25 dihydroxy vitamin d3 eller et af dets analoger til at styre udviklingen af renal knoglesygdom.